Health & Biotech
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Osteopore inks first ANZ distribution deal, adds ex-ResMed exec
Health & Biotech
Osteopore to work with Singapore medical school on 3D printed jaws
Health & Biotech
Osteopore attracts $8.5m from top-tier instos to expand its bone healing tech horizons
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Stockhead TV
StockTalk: How are ASX medtechs responding to skyrocketing healthcare spending?
Health & Biotech
How tech is changing healthcare, and where professional ASX investors are looking
IPO Watch
Biological scaffold play Aroa Biosurgery surges 87pc on ASX debut
Health & Biotech
Osteopore shares fly after bagging new tech
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Who’s ramping things up today?
Health & Biotech
Osteopore cracks billion dollar US bone healing market, shares surge
News
10 at 10: These ASX stocks are blowing their trumpets this morning
Health & Biotech
Medtech needs more than a TGA tick to hit the big $$$
Health & Biotech
Australia’s TGA says ‘yes’ to Osteopore’s bone healing devices
News
Rise and Shine: What you need to know before the ASX opens
Stockhead TV